AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03446612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Daprodustat will be available as 1 mg, 2 mg and 4 mg oral tablets. Daprodustat will be administered once daily by oral route without regard for food.
Study NCT03446612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa will be given as solution for injection for subcutaneous administration every 2 weeks.
Study NCT03446612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
Study NCT03446612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine
Description: Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
Study NCT03446612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Description: Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
Study NCT03446612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitroprusside
Description: Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
Study NCT03446612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-N-monomethyl arginine acetate (L-NMMA)
Description: L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
Study NCT03446612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-N-monomethyl arginine acetate (L-NMMA)
Description: L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
Study NCT00571519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoglitazone HCl
Description: 0.5 mg tablets administered orally, once daily
Study NCT00571519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivoglitazone HCl
Description: 1.0 mg tablets administered orally, once daily
Study NCT00571519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivoglitazone HCl
Description: 1.5 mg tablets administered orally, once daily
Study NCT00571519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets matching rivoglitazone tablets administered orally, once daily
Study NCT00571519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone HCl
Description: 15 mg capsules administered orally, once daily
Study NCT00571519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone HCl
Description: 30 mg capsules administered orally, once daily
Study NCT00571519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone HCl 45 mg
Description: 45 mg capsules administered orally, once daily
Study NCT00571519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules for pioglitazone administered orally, once daily
Study NCT00571519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Oral tablets. Rescue medication.
Study NCT00571519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Oral tablets. Rescue medication.
Study NCT00571519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Oral tablets. Rescue medication.
Study NCT02422589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib
Study NCT02422589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Study NCT02422589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Study NCT03470168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygenation Therapy
Description: Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
Study NCT03470168 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normobaric Oxygenation therapy
Description: Received the Normobaric Oxygen therapy treatment at 1 ATA for 90 minutes each day.
Study NCT01902693 — intervention group
Intervention type: OTHER
Intervention: No intervention for this study
Description: No intervention
Study NCT01268501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B multifocal contact lens
Description: Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
Study NCT03905876 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaire to evaluate psychological experience
Study NCT02321072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Study NCT02362555 — intervention group
Intervention type: OTHER
Intervention: no intervention was used in this observational study
Study NCT00950963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Counseling
Description: Patient were contacted on a periodic basis via telephone to address there diabetes care.
Study NCT00950963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Clinical Care
Description: Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
Study NCT01992523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor mashed pills
Description: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.
Study NCT01992523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor integral pills
Description: The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
Study NCT00345943 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Magnetic Resonance Imaging scans
Study NCT00345943 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: Neuropsychological tests
Study NCT01526005 — intervention group
Intervention type: DRUG
Intervention: Transdermal Nicotine Patch
Description: 1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total
Study NCT01526005 — intervention group
Intervention type: DRUG
Intervention: Transdermal Placebo Patch
Description: 1 patch per day; 8 weeks total
Study NCT02297646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Training
Study NCT02297646 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Endurance Training
Study NCT01882192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family physical activity planning
Description: This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for when, where, how, and what physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting.
Study NCT00618904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics - Lactobacillus and bifidobacterium
Description: Probiotics administered bid for 6 weeks.
Study NCT00618904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered bid for 6 weeks.
Study NCT02833818 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CAKE-intervention
Description: Increased protein and energy supplementation and conversations
Study NCT02833818 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CAKE-control
Description: nutrition according to established procedures
Study NCT02151799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominoplasty and liposuction
Study NCT03794297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study NCT02251184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggrenox
Study NCT02251184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole
Study NCT02251184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02251184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Study NCT02251184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Study NCT01023620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
Study NCT01023620 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Observation
Description: Participants will be observed for 16 weeks but will not receive drug
Study NCT02642328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIIT Training
Description: Circuit of high intensity interval training (HIIT) with Strength and Power Exercises for 4 minutes (20 sec of stimulus / 10 sec rest)
Study NCT02642328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Continuous aerobic exercise at 65% of VO2Max
Study NCT00814970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Complete SE Vascular Stent System
Description: Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
Study NCT02613975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positonal device
Description: positional device detects prone positional and will vibrate to cause patient to lie laterally
Study NCT03673449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SilkBridge
Description: SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.
Study NCT02632981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nonsurgical periodontal treatment
Description: Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
Study NCT02632981 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival crevicular fluid and saliva collection
Description: GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
Study NCT01572558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: Standard surgical treatment, normally laparoscopic appendectomy
Study NCT01572558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conservative, non-surgical treatment
Description: Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
Study NCT02298920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0914
Description: Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
Study NCT03462303 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sham tDCS and tyrosine depleted drink
Description: Transcranial direct current stimulation (sham) of the dlPFC in combination with a tyrosine and phenylalanine free product.
Study NCT03462303 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anodal tDCS and tyrosine depleted drink
Description: Transcranial direct current stimulation (anodal) of the dlPFC in combination with a tyrosine and phenylalanine free product.
Study NCT03462303 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS and balanced drink
Description: Transcranial direct current stimulation (sham) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
Study NCT03462303 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anodal tDCS and balanced drink
Description: Transcranial direct current stimulation (anodal) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
Study NCT00933972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4998452
Description: 20mg po single dose
Study NCT00101595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
Study NCT00793091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C-KAD Ophthalmic Solution
Description: 4 drops applied daily for 120 days
Study NCT00793091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 drops applied daily for 120 days
Study NCT04462445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study NCT03439553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ads display with target websites
Description: Ads are shown, but users are referred to control websites.
Study NCT03439553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ads display with control websites
Description: Ads are shown, but users are referred to control websites.
Study NCT03743623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurocytotron
Description: Neurocytotron utilizes a combination of instantaneous magnetic field and low-spectrum radiofrequency waves for therapeutic purpose. Its working principle is based on the theory of magnetic resonance.
Study NCT03368352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Dietary supplement melatonin
Study NCT03368352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxia
Description: Sleep in a hypoxic tent simulating high altitude
Study NCT00420342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)
Description: SH K 00641 A -Active study medication encapsulated tablet
Study NCT00420342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)
Description: SH K 00641 B - Active study medication encapsulated tablet
Study NCT00420342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
Description: Active control encapsulated tablet
Study NCT03743623 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same treatment procedures without being actually exposed to electromagnetic waves and magnetic field
Study NCT02661893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: A single oral dose of 40 milligram (mg) (=2\*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
Study NCT02661893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral dose of rifampin 600 mg (2\*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2\*300 mg) on Days 5 to 12.
Study NCT01546207 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: catheter-based ablation
Description: specific electrophysiological and mapping techniques of activation and entrainment mapping during ongoing VT. Substrate mapping and ablation (substrate modification.) catheter ablation - a medical procedure used to treat some types of arrhythmia
Study NCT04503902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib Tosilate Tablets
Description: In the dose exploration phase (phase I)，three doses of Donafenib tosylate tablets \[100 mg once a day (QD); 100 mg twice a day (BID); 200 mg, BID\] will be explored. In the dose expansion phase (phase II), patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
Study NCT04503902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: JS001 will be administrated by intravenous (i.v.) infusion once every 21 days
Study NCT05382624 — intervention group
Intervention type: PROCEDURE
Intervention: Abdominal circumference was measured at the umbilical level in the standing position at the end of a normal expiration.
Description: The operation time (the time from the beginning of the surgical incision until the end of surgery), anesthetic complications, such as nausea or vomiting, the number of patients requiring ephedrine and atropine, the total amount of intravenous fluid used, and the total amount of ephedrine used during surgery were recorded.
Study NCT01251601 — intervention group
Intervention type: OTHER
Intervention: Pharmacokinetics
Description: Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum
Study NCT04091854 — intervention group
Intervention type: DRUG
Intervention: HMS5552
Description: To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
Study NCT02601469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS
Description: twice daily for 28 days
Study NCT01162512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: physical activity counseling sessions will occur by telephone weekly for 2 months
Study NCT00530244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Description: Infant formula with 0.96% of fatty acids as DHA
Study NCT00530244 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard formula (Enfamil)
Description: This is a standard, commercially available infant formula.
Study NCT00899054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00
Description: P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
Study NCT00899054 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT)
Description: All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
Study NCT02079545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab (IV infusion)
Description: Participants will receive a single IV infusion of 100 mg sirukumab.
Study NCT02079545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab (SC injection with PFS-U)
Description: Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.
Study NCT01855945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine Influenza
Description: Comparison of different dosages of vaccines
Study NCT00550290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin PostOperatively
Description: Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.